Immucell Stock News

Annual Product Sales for 2021 Increased 25% over 2020 Annual Product Sales for 2021 Increased 25% over 2020

Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ET

Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ET

PORTLAND, Maine, Jan. 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets

ImmuCell (NASDAQ:ICCC) and Aspira Womens Health (NASDAQ:AWH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations. Analyst Recommendations This is a breakdown of recent ratings and price targets for ImmuCell and []

Global WholeHealth Partners (OTCMKTS:GWHP) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. Valuation & Earnings This table compares Global WholeHealth Partners and ImmuCells gross revenue, earnings per []

Santos and Oil Search merger now in the hands of the ICCC, DataCo reduces wholesale prices by 66 per cent for metro fibre connectivity services, and Treasurer Ling-Stuckey receives report on the Central Bank Act 2000 review. The business news you need to know. The post In brief: Santos submits application for Oil Search merger to ICCC and other business stories appeared first on Business Advantage PNG .

ImmuCell Corp (ICCC) CEO Michael Brigham on Q3 2021 Results - Earnings Call Transcript

Q3 2021 Net Income of $148,000 versus Q3 2020 Net Loss of ($323,000) Q3 2021 Net Income of $148,000 versus Q3 2020 Net Loss of ($323,000)

Q3 2021 Net Income of $148,000 versus Q3 2020 Net Loss of ($323,000) Q3 2021 Net Income of $148,000 versus Q3 2020 Net Loss of ($323,000)

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the

PORTLAND, Maine, Oct. 06, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets s

PORTLAND, Maine, Sept. 14, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets